Project Grant R01CA308976
Award Date 8/7/26
Completion Date 7/31/31
Dollars Obligated $647K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
- The National Cancer Institute awarded The Medical College of Wisconsin, Inc., $149,190 on January 21, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund basic research investigating the role of keratinocytes and the TRPM3 ion channel in chemotherapy-induced peripheral neuropathy (CIPN) pain. The research uses a mouse model of CIPN to examine how non-neuronal skin cells contribute to ongoing pain behaviors following paclitaxel chemotherapy exposure. In Aim 1, the...
- This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
- The National Cancer Institute, part of the National Institutes of Health, awarded $508,651 to the University of Wisconsin–Madison on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and exploit therapeutically the role of neuropeptide receptor PAC1 in tumor-infiltrating pericytes during melanoma progression. The research investigates how PACAP-expressing neurons within the melanoma microenvironment interact with PAC1-expressing pericytes to drive disease...
- The National Cancer Institute awarded $585,625 to the University of Wisconsin - Madison on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how nociceptor neurons, tumor cells, and pericytes interact through CGRP-RAMP1 signaling to drive melanoma progression and metastasis. The research targets the nociceptor neuron-tumor-pericyte axis within the melanoma metastatic microenvironment. Preliminary data from the recipient's laboratory demonstrates that nociceptor...
- The National Cancer Institute awarded the University of Wisconsin–Madison $634,644 on March 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate treatment of neuroinflammation caused by chemoradiation-induced dysphagia in head and neck cancer patients. The funded research tests whether glibenclamide (GLC) therapy combined with tongue exercise can mitigate radiation-induced peripheral neuropathy and improve swallowing function in a rat model of chemoradiation...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded Oregon Health & Science University $544,420 on August 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a clinical trial testing the efficacy of low-intensity vibration therapy in reducing chemotherapy-induced peripheral neuropathy symptoms and preserving functional mobility in cancer survivors. The research will evaluate whether low-intensity...
- The National Institute of Neurological Disorders and Stroke awarded Temple University $2,470,369 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate a cannabidiol (CBD) nanoemulsion formulation, SRIN-009, for treating chemotherapy-induced peripheral neuropathy (CIPN). The project addresses CIPN, a debilitating adverse effect affecting up to 75 percent of patients receiving certain chemotherapy regimens, characterized by pain,...
- The National Institute of Neurological Disorders and Stroke awarded the University of Rochester $2,197,287 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a Phase III confirmatory clinical trial of daily, wireless, home-based transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN). The trial will evaluate TENS efficacy in relieving neuropathic pain in cancer patients who have developed CIPN—a common...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $995,981 on September 9, 2025, under the Cancer Biology Research program (CFDA 93.396) to decipher the role of cancer pain-associated neuronal activity in driving malignancies, with work continuing through August 31, 2030. The research addresses the hypothesis that a feedforward mechanism exists between cancer pain-associated sensory neuron hyperactivity and malignant peripheral nerve sheath tumor (MPNST)...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University a $2.71 million Project Grant (effective August 6, 2025 through July 31, 2030) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN). The award supports research utilizing novel whole dorsal root ganglia (DRG) in vivo imaging technology to monitor sensory...